SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy
Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease
Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression
Abraxane and Gemcitabine Improves Overall Survival
Study Uncovers New Mechanism In Class of Chemotherapy Drugs
Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients
Genetic Test Identifies Patients With High Risk of Mortality
Memantine Can Delay Onset Of Cognitive Function Decline
Doxepin Rinse Reduces Pain In Radiation Therapy Patients
Zaltrap Receives Positive Opinion For European Market From CHMP
NCI-Approved CTEP Trials For the Month of November
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup - What happened at FDA? Replimune approval raises questions
